4 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Approved WMOCompleted
To gain more knowledge about the effects of SGLT2 inhibition on renal hemodynamics and the underlying mechanisms.
Approved WMOCompleted
To assess the safety and the efficacy on the activity part of the Steatosis Activity Fibrosis (SAF) histological score (inflammation and ballooning) of a 24-week treatment with two doses of lanifibranor (800, 1200 mg/24h) in NASH adult patients.
Approved WMOCompleted
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics